

Title (en)

PROANTHOCYANIDINS FOR THE TREATMENT OF AMYLOID AND ALPHA-SYNUCLEIN DISEASES

Title (de)

PROANTHOCYANIDINE ZUR BEHANDLUNG VON AMYLOID- UND ALPHA-SYNUCLEIN-KRANKHEITEN

Title (fr)

PROANTHOCYANIDINES DESTINEES AU TRAITEMENT DES AMYLOSES ET DES MALADIES INDUITES PAR ALPHA-SYNUCLEINE

Publication

EP 1377287 A4 20071114 (EN)

Application

EP 02719009 A 20020215

Priority

- US 0204764 W 20020215
- US 27686601 P 20010315
- US 93898701 A 20010824
- US 5362501 A 20011102
- US 0151131 W 20011102
- US 33872101 P 20011204
- US 33896901 P 20011210
- US 33903301 P 20011210

Abstract (en)

[origin: WO02076381A2] A method of treating an amyloid disease, or a disease characterized by alpha -synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed proanthocyanidins or a proanthocyanidin characterized by disclosed general formulae. A pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin and a pharmaceutically acceptable excipient. The therapeutic amount of the proanthocyanidin is selected for efficacy in treating amyloid, alpha -synuclein or NAC fibrillogenesis in a mammalian subject.

IPC 1-7

A61K 31/35; A61K 31/352; A61K 31/353; A61P 25/16; A61P 25/28; A61P 3/10

IPC 8 full level

C07D 311/62 (2006.01); **A61K 31/215** (2006.01); **A61K 31/35** (2006.01); **A61K 31/352** (2006.01); **A61K 31/353** (2006.01); **A61K 31/40** (2006.01); **A61K 36/00** (2006.01); **A61K 36/18** (2006.01); **A61K 39/385** (2006.01); **A61P 3/10** (2006.01); **A61P 25/16** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **C07B 63/00** (2006.01)

CPC (source: EP)

A61K 31/215 (2013.01); **A61K 31/353** (2013.01); **A61P 3/10** (2017.12); **A61P 25/16** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12)

Citation (search report)

- [X] WO 0030666 A1 20000602 - UNIV WASHINGTON [US]
- [PX] WO 0149307 A1 20010712 - PROTEOTECH INC [US], et al
- [X] US 5922756 A 19990713 - CHAN MARION MAN-YING [US]
- [A] WO 9945797 A1 19990916 - MARS INC [US], et al
- See references of WO 02076381A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02076381 A2 20021003; WO 02076381 A3 20021121; AU 2002250117 B2 20071129; AU 2002250117 B8 20021008; CA 2441099 A1 20021003; CA 2441099 C 20110419; EP 1377287 A2 20040107; EP 1377287 A4 20071114; JP 2005505497 A 20050224; JP 4380991 B2 20091209; NZ 528322 A 20050324

DOCDB simple family (application)

US 0204764 W 20020215; AU 2002250117 A 20020215; CA 2441099 A 20020215; EP 02719009 A 20020215; JP 2002574897 A 20020215; NZ 52832202 A 20020215